Patents Granted in Key Territories as Novexatin® Moves Closer to Further Clinical Development and Commercialization

NovaBiotics, has announced that it has further secured the global intellectual property position of its lead product, Novexatin® through recent patent grants in the US, EU and other territories worldwide. Novexatin® is a topical treatment for fungal nail infection and NovaBiotics’ recent patent grants protect the use of its core peptide technology in this and other related target indications.

The Company’s granted and pending IP not only protects the use of the core structure of Novexatin®, but of a related family of anti-infective peptides derived from the same technology platform. This is a critical milestone for the Company with key grants for its lead and follow-on products being secured a relatively early stage in their lifecycle.

NovaBiotics’ current antifungal product portfolio includes Novexatin® a phase 2b-ready clinical asset and Novamycin®, a candidate treatment for potentially life-threatening blood-stream and deep tissue yeast and mould infections (predominantly Candida).

In addition, NovaBiotics’ antibacterial peptide drug candidate, NP432 and novel mucolytic agent NM001 are now at the early proof of efficacy stage for the treatment of respiratory infections including multi-drug resistant forms and those associated with cystic fibrosis.

Dr Deborah O’Neil, Founder, commented: “Recent patent grants in key territories for our expanding product portfolio is an important step in NovaBiotics’ development, particularly as we bring our lead product Novexatin® closer to market. This undoubtedly adds significant further value for the interested parties with whom we are in ongoing discussions for Novexatin®.”